Our goal
Safe births and healthy children
The birth of a child is a natural part of life, yet simultaneously wondrous and magical. Throughout the entire pregnancy, everything and everyone is focused on ensuring the child is born healthy.
We continuously ask ourselves how we can help improve care for the unborn child and the mother. We develop medical products that reliably and accurately monitor the heartbeat of both woman and unborn child, while also offering maximum comfort.
Perinatal Research
Better Care for Mother and Child
Nemo Healthcare was founded in 2010 and emerged from close collaboration between the Máxima Medical Center Veldhoven (MMC) and Eindhoven University of Technology (TU/e), both located in the Netherlands.
In the 1980s, they jointly investigated the hemodynamic signals of newborns in the Neonatal Intensive Care Unit (NICU). By using advanced signal processing techniques, new insights were gained. These proved valuable for diagnosing or treating sick newborns. In 2000, the research was expanded to include analyzing the cardiac activity of the unborn child. This analysis was aimed at obtaining new information that could be used to improve the monitoring of the unborn child.
History
Comfortable and Reliable
In 2005, a project was launched to develop methods for monitoring the health of unborn children using electrophysiological recordings. This project was funded by the Dutch Foundation for Applied Sciences (STW). These recordings provided information on uterine activity and fetal cardiac activity in a non-invasive and comfortable way for the pregnant woman. Moreover, the information proved to be more accurate and reliable than all other existing non-invasive methods.
On the market
To fully utilize the potential of this new technology, the methods needed to be further developed into clinical applications.
With support from two STW grants, the technology for monitoring uterine activity was further developed into a clinically applicable device called PUREtrace™. In 2011, a consortium of investors invested in the company, providing the necessary funding to enable certification and commercialization of PUREtrace. Simultaneously, we began developing technology to measure fetal cardiac activity.
With a second round of investment in 2016 and an EU Horizon 2020 SME (small and medium-sized enterprise) Instrument phase 2 grant, we were able to complete the development of our fetal monitoring technology. At the end of 2018, the Nemo Fetal Monitoring System was launched for hospital use. This product is now used daily in several European countries, and the number of users is steadily increasing. In 2022, NemoRemote was launched, a product that makes it possible to monitor pregnant women at home.